{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:31:43Z","timestamp":1782437503315,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11102-023-01341-4","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T11:01:57Z","timestamp":1690801317000},"page":"561-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metastatic pituitary tumors: an institutional case series"],"prefix":"10.1007","volume":"26","author":[{"given":"Alexander G.","family":"Yearley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Chalif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saksham","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua I.","family":"Chalif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Bernstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Nawabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Arnaout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"7","key":"1341_CR1","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","volume":"108","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive pituitary tumors and Pituitary Carcinomas: from Pathology to Treatment. J Clin Endocrinol Metabolism 108(7):1585\u20131601. https:\/\/doi.org\/10.1210\/clinem\/dgad098","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1341_CR2","doi-asserted-by":"publisher","unstructured":"Beauchesne P, Trouillas J, Barral F, Brunon J (1995) : Gonadotropic pituitary carcinoma: case report. Neurosurgery. 37(4), 810\u2013815; discussion 815\u2013816 https:\/\/doi.org\/10.1227\/00006123-199510000-00027","DOI":"10.1227\/00006123-199510000-00027"},{"issue":"4","key":"1341_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/(sici)1097-0142(19970215)79:4<804::aid-cncr18>3.0.co;2-3","volume":"79","author":"PJ Pernicone","year":"1997","unstructured":"Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr et al (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804\u2013812. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19970215)79:4<804::aid-cncr18>3.0.co;2-3","journal-title":"Cancer"},{"issue":"3","key":"1341_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00062-011-0073-6","volume":"21","author":"J Faehndrich","year":"2011","unstructured":"Faehndrich J, Weidauer S, Pilatus U, Oszvald A, Zanella FE, Hattingen E (2011) Neuroradiological viewpoint on the diagnostics of space-occupying brain lesions. Clin Neuroradiol 21(3):123\u2013139. https:\/\/doi.org\/10.1007\/s00062-011-0073-6","journal-title":"Clin Neuroradiol"},{"issue":"4","key":"1341_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1530\/eje-18-0795","volume":"181","author":"F Santos-Pinheiro","year":"2019","unstructured":"Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown PD et al (2019) Treatment and long-term outcomes in pituitary carcinoma: a cohort study. Eur J Endocrinol 181(4):397\u2013407. https:\/\/doi.org\/10.1530\/eje-18-0795","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1341_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/nop\/npv059","volume":"3","author":"Y Ji","year":"2016","unstructured":"Ji Y, Vogel RI, Lou E (2016) Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. Neurooncol Pract 3(3):188\u2013195. https:\/\/doi.org\/10.1093\/nop\/npv059","journal-title":"Neurooncol Pract"},{"issue":"2","key":"1341_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10143-014-0525-y","volume":"37","author":"TM Hansen","year":"2014","unstructured":"Hansen TM, Batra S, Lim M, Gallia GL, Burger PC, Salvatori R et al (2014) Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev 37(2):279\u2013285 discussion 285 \u2013 276. https:\/\/doi.org\/10.1007\/s10143-014-0525-y","journal-title":"Neurosurg Rev"},{"issue":"3","key":"1341_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/eje-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a european Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276. https:\/\/doi.org\/10.1530\/eje-17-0933","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1341_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1023\/a:1009975009924","volume":"1","author":"GA Kaltsas","year":"1998","unstructured":"Kaltsas GA, Grossman AB (1998) Malignant pituitary tumours. Pituitary 1(1):69\u201381. https:\/\/doi.org\/10.1023\/a:1009975009924","journal-title":"Pituitary"},{"issue":"1","key":"1341_CR10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/eje-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013g24. https:\/\/doi.org\/10.1530\/eje-17-0796","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1341_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/nm.3729","volume":"20","author":"Z Zheng","year":"2014","unstructured":"Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD et al (2014) Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20(12):1479\u20131484. https:\/\/doi.org\/10.1038\/nm.3729","journal-title":"Nat Med"},{"issue":"2","key":"1341_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3171\/jns.2003.99.2.0402","volume":"99","author":"F Roncaroli","year":"2003","unstructured":"Roncaroli F, Nos\u00e9 V, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr et al (2003) Gonadotropic pituitary carcinoma: HER-2\/neu expression and gene amplification. Report of two cases. J Neurosurg 99(2):402\u2013408. https:\/\/doi.org\/10.3171\/jns.2003.99.2.0402","journal-title":"J Neurosurg"},{"issue":"6","key":"1341_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1530\/EJE-10-0629","volume":"163","author":"M Losa","year":"2010","unstructured":"Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M et al (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843\u2013851. https:\/\/doi.org\/10.1530\/EJE-10-0629","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1341_CR14","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P et al (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a french multicenter experience. J Clin Endocrinol Metab 95(10):4592\u20134599. https:\/\/doi.org\/10.1210\/jc.2010-0644","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1341_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98(3):1130\u20131136. https:\/\/doi.org\/10.1210\/jc.2012-2924","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR16","doi-asserted-by":"publisher","unstructured":"Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M et al (2014) : High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery. 74(4), E447-455; discussion E455 https:\/\/doi.org\/10.1227\/NEU.0000000000000251","DOI":"10.1227\/NEU.0000000000000251"},{"issue":"4","key":"1341_CR17","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schr\u00f8der HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100(4):1689\u20131698. https:\/\/doi.org\/10.1210\/jc.2014-4350","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR18","doi-asserted-by":"publisher","first-page":"587893","DOI":"10.1155\/2015\/587893","volume":"2015","author":"OD Bruno","year":"2015","unstructured":"Bruno OD, Ju\u00e1rez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C et al (2015) Temozolomide Therapy for Aggressive Pituitary Tumors: results in a small series of patients from Argentina. Int J Endocrinol 2015:587893. https:\/\/doi.org\/10.1155\/2015\/587893","journal-title":"Int J Endocrinol"},{"issue":"8","key":"1341_CR19","first-page":"9712","volume":"8","author":"YQ Wang","year":"2015","unstructured":"Wang YQ, Fan T, Zhao XG, Liang C, Qi XL, Li JY (2015) Pituitary carcinoma with intraspinal metastasis: report of two cases and review of the literature. Int J Clin Exp Pathol 8(8):9712\u20139717","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"1341_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/nop\/npx013","volume":"5","author":"JT Jordan","year":"2018","unstructured":"Jordan JT, Miller JJ, Cushing T, Seijo M, Batchelor TT, Arrillaga-Romany IC et al (2018) Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract 5(1):64\u201368. https:\/\/doi.org\/10.1093\/nop\/npx013","journal-title":"Neurooncol Pract"},{"issue":"3","key":"1341_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-018-0872-8","volume":"21","author":"F Yoo","year":"2018","unstructured":"Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB (2018) Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary 21(3):290\u2013301. https:\/\/doi.org\/10.1007\/s11102-018-0872-8","journal-title":"Pituitary"},{"issue":"2","key":"1341_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5306\/wjco.v11.i2.91","volume":"11","author":"L Xu","year":"2020","unstructured":"Xu L, Khaddour K, Chen J, Rich KM, Perrin RJ, Campian JL (2020) Pituitary carcinoma: two case reports and review of literature. World J Clin Oncol 11(2):91\u2013102. https:\/\/doi.org\/10.5306\/wjco.v11.i2.91","journal-title":"World J Clin Oncol"},{"key":"1341_CR23","doi-asserted-by":"publisher","first-page":"968692","DOI":"10.3389\/fendo.2022.968692","volume":"13","author":"S Du Four","year":"2022","unstructured":"Du Four S, Van Der Veken J, Duerinck J, Vermeulen E, Andreescu CE, Bruneau M et al (2022) Pituitary carcinoma - case series and review of the literature. Front Endocrinol (Lausanne) 13:968692. https:\/\/doi.org\/10.3389\/fendo.2022.968692","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1341_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11102-010-0249-0","volume":"13","author":"Q Lau","year":"2010","unstructured":"Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 13(4):367\u2013379. https:\/\/doi.org\/10.1007\/s11102-010-0249-0","journal-title":"Pituitary"},{"issue":"2","key":"1341_CR25","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1530\/jme-12-0113","volume":"49","author":"O Mete","year":"2012","unstructured":"Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49(2):R69\u201378. https:\/\/doi.org\/10.1530\/jme-12-0113","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"1341_CR26","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4):765\u2013770 discussion 770 \u2013 761","journal-title":"Neurosurgery"},{"key":"1341_CR27","doi-asserted-by":"publisher","unstructured":"Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E et al (2006) : Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 59(2), 341\u2013353; discussion 341\u2013353 https:\/\/doi.org\/10.1227\/01.Neu.0000223437.51435.6e","DOI":"10.1227\/01.Neu.0000223437.51435.6e"},{"key":"1341_CR28","doi-asserted-by":"publisher","unstructured":"Raymond P, Raverot G, Ilie M-D (2023) Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review. Endocrine-related Cancer 30(5). https:\/\/doi.org\/10.1530\/ERC-22-0338. e220338","DOI":"10.1530\/ERC-22-0338"},{"key":"1341_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","volume":"106","author":"O Casar-Borota","year":"2021","unstructured":"Casar-Borota O, Boldt HB, Engstr\u00f6m BE, Andersen MS, Baussart B, Bengtsson D et al (2021) Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations. J Clin Endocrinol Metab 106:1183\u20131194","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","volume":"106","author":"AV Uzilov","year":"2021","unstructured":"Uzilov AV, Taik P, Cheesman KC, Javanmard P, Ying K, Roehnelt A et al (2021) USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors. J Clin Endocrinol Metab 106:826\u2013842","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR31","doi-asserted-by":"publisher","unstructured":"Tatsi C, Stratakis CA (2019) The Genetics of Pituitary Adenomas. J Clin Med 9(1). https:\/\/doi.org\/10.3390\/jcm9010030","DOI":"10.3390\/jcm9010030"},{"issue":"5","key":"1341_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.20945\/2359-3997000000144","volume":"63","author":"AC Cohen","year":"2019","unstructured":"Cohen AC, Goldney DC, Danilowicz K, Manavela M, Rossi MA, G\u00f3mez RM et al (2019) Long-term outcome after bilateral adrenalectomy in Cushing\u2019s disease with focus on Nelson\u2019s syndrome. Arch Endocrinol Metab 63(5):470\u2013477. https:\/\/doi.org\/10.20945\/2359-3997000000144","journal-title":"Arch Endocrinol Metab"},{"issue":"10","key":"1341_CR33","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1210\/jc.2013-1470","volume":"98","author":"K Ritzel","year":"2013","unstructured":"Ritzel K, Beuschlein F, Mickisch A, Osswald A, Schneider HJ, Schopohl J et al (2013) Outcome of bilateral adrenalectomy in Cushing\u2019s syndrome: a systematic review. J Clin Endocrinol Metabolism 98(10):3939\u20133948. https:\/\/doi.org\/10.1210\/jc.2013-1470","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"6","key":"1341_CR34","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3171\/2016.9.Jns161163","volume":"127","author":"CS Graffeo","year":"2017","unstructured":"Graffeo CS, Perry A, Carlstrom LP, Meyer FB, Atkinson JLD, Erickson D et al (2017) Characterizing and predicting the Nelson-Salassa syndrome. J Neurosurg 127(6):1277\u20131287. https:\/\/doi.org\/10.3171\/2016.9.Jns161163","journal-title":"J Neurosurg"},{"issue":"9","key":"1341_CR35","doi-asserted-by":"publisher","first-page":"e5595","DOI":"10.7759\/cureus.5595","volume":"11","author":"LP Carlstrom","year":"2019","unstructured":"Carlstrom LP, Graffeo CS, Perry A, Stokken JK, Van Gompel JJ (2019) Nelson-Salassa syndrome progressing to Pituitary Carcinoma: a Case Report and Review of the literature. Cureus 11(9):e5595. https:\/\/doi.org\/10.7759\/cureus.5595","journal-title":"Cureus"},{"key":"1341_CR36","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1210\/jcem-19-12-1523","volume":"19","author":"RM Salassa","year":"1959","unstructured":"Salassa RM, Kearns TP, Kernohan JW, Sprague RG, Maccarty CS (1959) Pituitary tumors in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 19:1523\u20131539. https:\/\/doi.org\/10.1210\/jcem-19-12-1523","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1341_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3171\/jns.2002.96.2.0352","volume":"96","author":"TA Gaffey","year":"2002","unstructured":"Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F et al (2002) Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 96(2):352\u2013360. https:\/\/doi.org\/10.3171\/jns.2002.96.2.0352","journal-title":"J Neurosurg"},{"issue":"4","key":"1341_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/eje-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593\u2013605. https:\/\/doi.org\/10.1530\/eje-22-0440","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1341_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2265.2008.03487.x","volume":"71","author":"AI McCormack","year":"2009","unstructured":"McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA et al (2009) Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71(2):226\u2013233. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03487.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1341_CR40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/eje-09-0389","volume":"161","author":"C Hagen","year":"2009","unstructured":"Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161(4):631\u2013637. https:\/\/doi.org\/10.1530\/eje-09-0389","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1341_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.humpath.2006.07.014","volume":"38","author":"K Kovacs","year":"2007","unstructured":"Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD et al (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38(1):185\u2013189. https:\/\/doi.org\/10.1016\/j.humpath.2006.07.014","journal-title":"Hum Pathol"},{"issue":"11","key":"1341_CR42","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr, Vance ML et al (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280\u2013290. https:\/\/doi.org\/10.1210\/jc.2010-0441","journal-title":"J Clin Endocrinol Metab"},{"key":"1341_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","volume":"41","author":"W Touma","year":"2017","unstructured":"Touma W, Hoostal S, Peterson RA, Wiernik A, SantaCruz KS, Lou E (2017) Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection. J Clin Neurosci 41:75\u201377. https:\/\/doi.org\/10.1016\/j.jocn.2017.02.052","journal-title":"J Clin Neurosci"},{"issue":"11","key":"1341_CR44","doi-asserted-by":"publisher","first-page":"R559","DOI":"10.1530\/erc-18-0228","volume":"25","author":"D Dworakowska","year":"2018","unstructured":"Dworakowska D, Grossman AB (2018) Aggressive and malignant pituitary tumours: state-of-the-art. Endocr Relat Cancer 25(11):R559\u2013r575. https:\/\/doi.org\/10.1530\/erc-18-0228","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"1341_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/erc-22-0037","volume":"29","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Vasiljevic A, Jouanneau E, Raverot G (2022) Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocr Relat Cancer 29(7):415\u2013426. https:\/\/doi.org\/10.1530\/erc-22-0037","journal-title":"Endocr Relat Cancer"},{"key":"1341_CR46","doi-asserted-by":"publisher","first-page":"773905","DOI":"10.3389\/fonc.2021.773905","volume":"11","author":"C Dai","year":"2021","unstructured":"Dai C, Liang S, Sun B, Li Y, Kang J (2021) Anti-VEGF therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: a review. Front Oncol 11:773905. https:\/\/doi.org\/10.3389\/fonc.2021.773905","journal-title":"Front Oncol"},{"issue":"10","key":"1341_CR47","doi-asserted-by":"publisher","first-page":"bvab133","DOI":"10.1210\/jendso\/bvab133","volume":"5","author":"AL Lin","year":"2021","unstructured":"Lin AL, Tabar V, Young RJ, Cohen M, Cuaron J, Yang TJ et al (2021) Synergism of checkpoint inhibitors and peptide receptor Radionuclide Therapy in the treatment of Pituitary Carcinoma. J Endocr Soc 5(10):bvab133. https:\/\/doi.org\/10.1210\/jendso\/bvab133","journal-title":"J Endocr Soc"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01341-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01341-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01341-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:12:37Z","timestamp":1695885157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01341-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01341-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"7 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Mass General Brigham Institutional Review Board (Protocol #2015P002352).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"JDB has an equity position in Treovir Inc., an oHSV clinical stage company and is a member of the POCKiT Diagnostics, Centile Bioscience and NeuroX1 Boards of Scientific Advisors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}